Phase 1 dose-escalation trial combining sulfasalazine and stereotactic radiosurgery in patients with recurrent glioblastoma.

Redox Biol · 2026 · PMC13251504 · PMID 42229231

Europe PMC DOI

hedged sentences

0.0520

closest p · 1.0× alpha

0.0630

boldest claim

The sentences

borderline significantp = 0.052so close (0.05 < p ≤ 0.1)

4 A and B and C), with a mean change in SUV max from baseline to M1 post treatment of −0.78 (95% CI: −1.57 to 0.01) showing a borderline significant reduction (p = 0.052).

also in 11,409 other papers

did not reach statistical significancep = 0.063so close (0.05 < p ≤ 0.1)

Pseudoprogression was observed more frequently in trial participants (6/11; 54.5%) than controls (1/11; 9.1%), although this difference did not reach statistical significance, p = 0.063.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.